Related Experiment Video
Updated: Jun 28, 2026
A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation
Published on: August 30, 2019
Mechanistic Study on the Treatment of Acute Lung Injury with Qingwen Baidu Decoction based on NLRP3 Inflammasome
Jinhui Feng1, Xiangzheng Mao1, Wenting Wang1
1School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China.
Introduction:
Qingwen Baidu Decoction (QWBD), a classical traditional Chinese medicine formula, has demonstrated clinical efficacy in managing acute lung injury (ALI). However, the precise mechanisms underlying its protective effects remain poorly characterized.
Methods:
Major bioactive constituents of QWBD were identified through high-performance liquid chromatography (HPLC). Lipopolysaccharide (LPS)-induced in vivo and in vitro inflammatory models were established to evaluate therapeutic outcomes. Pulmonary edema severity was assessed via lung wet-to-dry weight ratio (W/D), while histopathological alterations were examined through hematoxylin-eosin (H&E) staining and transmission electron microscopy (TEM). Myeloperoxidase (MPO) activity and inflammatory cytokine levels were quantified to determine neutrophil activation and inflammatory responses. Mechanistic insights were obtained through immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB) targeting the NLRP3 inflammasome pathway.
Results:
HPLC analysis identified four principal bioactive components in QWBD. Treatment significantly attenuated pulmonary edema, ameliorated alveolar structural damage, and restored ultrastructural integrity of type II pneumocytes in ALI rats. QWBD significantly suppressed MPO activity and reduced pro-inflammatory cytokine levels compared to the LPS-treated group. IHC/IF revealed potent inhibition of cysteine-aspartic protease-1 (Caspase-1) and NOD-like receptor protein 3 (NLRP3) expression, while WB confirmed downregulation of NLRP3 inflammasome- associated proteins.
Discussion:
QWBD alleviates ALI by inhibiting NLRP3 inflammasome activation and upstream regulators, thereby attenuating pro-inflammatory cytokine maturation. Its multi-component composition confers advantages over single-target agents while potentially avoiding the broad immunosuppression associated with dexamethasone. Clinical validation of its therapeutic potential remains warranted.
Conclusion:
QWBD protects against ALI by implying NLRP3 inflammasome suppression, demonstrating promise as a multi-targeted therapy for inflammatory lung disorders.
